CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Highlights Charles River Laboratories International, Inc.

Stocks

CRL

US1598641074

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:19:02 2026-07-01 EDT			5-day change	1st Jan Change
234.89 ^USD	+3.57%		+16.06%	+17.59%

07:26am	Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating	MT
06-18	Charles River Laboratories International, Inc. and Eli Lilly and Company Enter Collaboration to Optimize Ai/Ml Platform Through Nonclinical Testing Expertise	CI

Highlights

05-13	Charles River Laboratories, Medipost Sign MoU on GMP-Compliant Testing	MT
05-11	Charles River Laboratories International, Inc. Approves Ratification of PricewaterhouseCoopers LLP as Independent Auditors	CI
05-11	Charles River Laboratories International, Inc. Accelerates Digital Pathology with Ai-Powered End-To-End Workflow	CI
05-08	Charles River Laboratories International, Inc. Seeks M&A Opportunities	CI
05-07	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.	CI
05-07	Charles River Laboratories International, Inc. Reports Earnings Results for the First Quarter Ended March 28, 2026	CI
05-07	Charles River Laboratories Q1 Adjusted Earnings Decline, Revenue Rises; Maintains 2026 Earnings Guidance	MT
05-07	(CRL) Charles River Laboratories International Expects 2026 Non-GAAP EPS Range $10.80 - $11.30, vs. FactSet Est of $11.08	MT
05-07	Earnings Flash (CRL) Charles River Laboratories International, Inc. Posts Q1 Adjusted EPS $2.06 per Share, vs. FactSet Est of $1.94	MT
05-07	Charles River beats quarterly estimates on steady demand for drug development services	RE
05-07	Earnings Flash (CRL) Charles River Laboratories International, Inc. Reports Q1 Revenue $995.8M, vs. FactSet Est of $977.5M	MT
05-07	Earnings Flash (CRL) Charles River Laboratories International, Inc. Reports Q1 Revenue $995.8M, vs. FactSet Est of $977.5M	MT
05-07	Charles River Laboratories International, Inc. Reports Consolidated Impairment Charges Results for the Quarter Ended March 28, 2026	CI
05-07	Charles River Laboratories International, Inc. Revises Earnings Guidance for 2026	CI
05-05	GI Manager L.P. completed the acquisition of Contract Development and Manufacturing Products and Services and Cell Solutions Businesses from Charles River Laboratories International, Inc..	CI
04-30	Charles River Laboratories Launches Rat in Vitro Fertility Services	CI
03-05	Therna Biosciences, Inc. Announces Collaboration with Charles River to Advance Single-Patient Personalized RNA Therapeutics	CI
02-25	GI Manager L.P. signed a definitive agreement to acquire Contract Development and Manufacturing Products and Services and Cell Solutions Businesses from Charles River Laboratories International, Inc..	CI
02-25	Charles River Laboratories to Sell Certain European Assets, Businesses; Full-Year 2026 Guidance Updated	MT
02-25	Charles River Laboratories International, Inc. Revises Earnings Guidance for 2026	CI
02-25	(CRL) Charles River Laboratories Expects 2026 Adjusted EPS Including Impact of Planned Divestitures Range $10.80 - $11.30	MT
02-18	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.	CI
02-18	Charles River Laboratories International, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 27, 2025	CI
02-18	Charles River Laboratories International, Inc. Announces Executive Appointments	CI
02-18	Charles River forecasts upbeat 2026 profit on improved demand for drug development services	RE